Age, Gender, and Laterality of Retinal Vascular Occlusion: A Retrospective Study from the IRIS® Registry.


Journal

Ophthalmology. Retina
ISSN: 2468-6530
Titre abrégé: Ophthalmol Retina
Pays: United States
ID NLM: 101695048

Informations de publication

Date de publication:
02 2022
Historique:
received: 28 10 2020
revised: 17 04 2021
accepted: 06 05 2021
pubmed: 16 5 2021
medline: 11 3 2022
entrez: 15 5 2021
Statut: ppublish

Résumé

Retinal vascular occlusion is a leading cause of profound irreversible visual loss, but the understanding of the disease is insufficient. We systematically investigated the age, gender, and laterality at the onset of retinal artery occlusion (RAO) and retinal vein occlusion (RVO) in the Intelligent Research in Sight (IRIS®) Registry. Retrospective registry cohort. Patients with retinal vascular occlusion participating in the IRIS® Registry. Patients who received a diagnosis of retinal vascular occlusion between 2013 and 2017 were included. Those with unspecified gender or laterality were excluded when conducting the relevant analyses. Patients were categorized into RAO, with subtypes transient retinal artery occlusion (TRAO), partial retinal artery occlusion (PRAO), branch retinal artery occlusion (BRAO), and central retinal artery occlusion (CRAO), and into RVO, with subtypes venous engorgement (VE), branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO). Age was evaluated as a categorical variable (5-year increments). We investigated the association of age, gender, and laterality with the onset frequency of retinal vascular occlusion subtypes. The frequency of onset of RAO and RVO subtypes by age, gender and laterality. A total of 1 251 476 patients with retinal vascular occlusion were included, 23.8% of whom had RAO, whereas 76.2% had RVO. Of these, 1 248 656 and 798 089 patients were selected for analyses relevant to gender and laterality, respectively. The onset frequency of all subtypes increased with age. PRAO, BRAO, CRAO, and CRVO presented more frequently in men (53.5%, 51.3%, 52.6%, and 50.4%, respectively), whereas TRAO, VE, and BRVO presented more frequently in women (54.9%, 56.0%, and 54.5% respectively). All RAO subtypes and BRVO showed a right-eye onset preference (TRAO, 51.7%; PRAO, 54.4%; BRAO, 53.5%; CRAO, 53.4%; and BRVO, 51.0%), whereas VE and CRVO exhibited a left-eye onset preference (53.3% and 50.9%, respectively). Although retinal vascular occlusion incidence increases with age regardless of subtypes, we found various subtype-specific disease-onset differences related to gender and, in particular, ocular laterality. These findings may improve understanding of the specific cause of retinal vascular occlusions of different subtypes and their relationships with structural and anatomic asymmetries of the vascular system.

Identifiants

pubmed: 33991710
pii: S2468-6530(21)00163-9
doi: 10.1016/j.oret.2021.05.004
pmc: PMC9178780
mid: NIHMS1812408
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

161-171

Subventions

Organisme : NEI NIH HHS
ID : K23 EY029246
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY026877
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG060942
Pays : United States

Informations de copyright

Copyright © 2021 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Références

Ophthalmology. 2018 Aug;125(8):1273-1278
pubmed: 29454658
Invest Ophthalmol Vis Sci. 2014 Jun 06;55(7):4057-62
pubmed: 24906854
Am J Ophthalmol. 2012 Oct;154(4):645-652.e1
pubmed: 22809785
Eur J Intern Med. 2017 Oct;44:44-48
pubmed: 28684050
Blood Coagul Fibrinolysis. 2007 Jun;18(4):321-6
pubmed: 17473572
Eur J Med Res. 2007 Dec 14;12(12):595-603
pubmed: 18024271
Ophthalmology. 2018 Apr;125(4):522-528
pubmed: 29146306
Ophthalmology. 2020 Feb;127(2):151-158
pubmed: 31611015
Biomed Res Int. 2015;2015:374616
pubmed: 26558268
Ophthalmology. 2018 May;125(5):676-682
pubmed: 29336897
Ophthalmology. 2010 Feb;117(2):313-9.e1
pubmed: 20022117
Medicine (Baltimore). 2016 Apr;95(14):e3281
pubmed: 27057891
Med Glas (Zenica). 2014 Feb;11(1):110-4
pubmed: 24496350
BMC Ophthalmol. 2017 Sep 2;17(1):162
pubmed: 28865424
Int J Ophthalmol. 2020 Mar 18;13(3):431-437
pubmed: 32309180
Am J Ophthalmol. 1993 Sep 15;116(3):286-96
pubmed: 8357052
Mater Sociomed. 2019 Jun;31(2):84-87
pubmed: 31452630
PLoS One. 2018 Aug 9;13(8):e0201627
pubmed: 30091989
Arch Intern Med. 1998 Mar 23;158(6):585-93
pubmed: 9521222
Br J Ophthalmol. 2008 Oct;92(10):1316-9
pubmed: 18684751
J Hypertens. 2019 Jul;37(7):1372-1383
pubmed: 31145709
BMC Ophthalmol. 2014 Nov 27;14:147
pubmed: 25428529
J Biomech Eng. 2019 May 22;:
pubmed: 31116368
Ophthalmologe. 2016 Jun;113(6):463-8
pubmed: 27277752
Clin Exp Ophthalmol. 2018 Apr;46(3):260-265
pubmed: 28752913
Stroke. 2020 Mar;51(3):800-807
pubmed: 31951154
Clin Appl Thromb Hemost. 2008 Jul;14(3):286-94
pubmed: 18160589
J Thromb Haemost. 2015 Jul;13(7):1254-63
pubmed: 25894549
Ophthalmol Glaucoma. 2020 Jul - Aug;3(4):253-261
pubmed: 33008558
J Ophthalmol. 2014;2014:724780
pubmed: 25009743
Ophthalmology. 2018 Aug;125(8):1143-1148
pubmed: 29342435
Arch Ophthalmol. 1996 May;114(5):545-54
pubmed: 8619763
Clin Lymphoma Myeloma. 2009 Mar;9(1):97-9
pubmed: 19362986
J Stroke Cerebrovasc Dis. 2020 Feb;29(2):104446
pubmed: 31837921
Ophthalmology. 2014 Jun;121(6):1274-80
pubmed: 24491641
Arch Ophthalmol. 1996 Oct;114(10):1243-7
pubmed: 8859084
Ophthalmic Epidemiol. 2018 Jun;25(3):220-226
pubmed: 29190171
Prog Retin Eye Res. 2014 Jul;41:1-25
pubmed: 24769221
Ophthalmology. 2009 Oct;116(10):1928-36
pubmed: 19577305
Circulation. 2012 Aug 21;126(8):934-41
pubmed: 22829023
Ophthalmology. 2018 Oct;125(10):1646-1653
pubmed: 29779683
Medicine (Abingdon). 2020 Sep;48(9):561-566
pubmed: 32837228
BMJ. 2018 Aug 15;362:k2562
pubmed: 30111634
J Glob Health. 2019 Jun;9(1):010427
pubmed: 31131101
Ophthalmology. 2015 Sep;122(9):1881-8
pubmed: 26231133

Auteurs

Yangjiani Li (Y)

Schepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China.

Nathan E Hall (NE)

Schepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.

Suzann Pershing (S)

Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California, USA; Department of Ophthalmology, VA Palo Alto Health Care System, Palo Alto, California, USA.

Leslie Hyman (L)

Wills Eye Hospital, Philadelphia, Pennsylvania, USA.

Julia A Haller (JA)

Wills Eye Hospital, Philadelphia, Pennsylvania, USA.

Aaron Y Lee (AY)

eScience Institute, University of Washington, Seattle, Washington, USA; Department of Ophthalmology, University of Washington, Seattle, Washington, USA.

Cecilia S Lee (CS)

Department of Ophthalmology, University of Washington, Seattle, Washington, USA.

Michael Chiang (M)

Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, USA.

Flora Lum (F)

American Academy of Ophthalmology, San Francisco, California, USA.

Joan W Miller (JW)

Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.

Alice Lorch (A)

Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.

Tobias Elze (T)

Schepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: Tobias_Elze@meei.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH